Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:27 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,569 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Regimen Clear all
Completed Phase 2 Interventional Results available

A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)

NCT04519658
View directory record Official record
Conditions
Resistant Hypertension
Interventions
CIN-107, Placebo
Drug
Lead sponsor
CinCor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
80
States / cities
Birmingham, Alabama • Saraland, Alabama • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Nov 3, 2026, 5:27 AM EST
Recruiting Phase 4 Interventional

Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

NCT07058155
View directory record Official record
Conditions
Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
Interventions
Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program
Procedure · Drug · Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 3, 2026, 5:27 AM EST
Active, not recruiting Not applicable Interventional

Texting for Diabetes

NCT03025984
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Texting
Behavioral
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Nov 3, 2026, 5:27 AM EST
Completed Not applicable Interventional

fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults

NCT01320748
View directory record Official record
Conditions
Substance Abuse, Substance Dependence, Alcohol Abuse, Drug Use, Relapse
Interventions
Dual Processing, Relapse Prevention
Behavioral
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Nov 3, 2026, 5:27 AM EST
Completed Phase 1Phase 2 Interventional Results available

Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

NCT01660607
View directory record Official record
Conditions
Myeloid Leukemia, Chronic, Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS), Lymphoma, Non-Hodgkin, Acute Lymphoblastic Leukemia (ALL), Myeloproliferative Syndrome, Acute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia
Interventions
CD34+ Hematopoietic Progenitor Cells (HSPC), Regulatory T-Cells (Treg), Conventional T-Cells (Tcon), Myeloablative Conditioning Regimen
Biological · Procedure
Lead sponsor
Stanford University
Other
Eligibility
13 Years to 73 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Nov 3, 2026, 5:27 AM EST
Completed Phase 2 Interventional Results available

Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis

NCT02761993
View directory record Official record
Conditions
Periodontal Disease
Interventions
ST266, Saline (0.9% NaCl)
Biological · Drug
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 85 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Cambridge, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Nov 3, 2026, 5:27 AM EST
Completed Not applicable Interventional

Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers

NCT01552447
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
EpiFix, Compression Therapy
Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Boca Raton, Florida • Framingham, Massachusetts • Tulsa, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Nov 3, 2026, 5:27 AM EST
Not yet recruiting Not applicable Interventional

CGM Use in Heart Failure

NCT07045298
View directory record Official record
Conditions
Heart Failure, Diabetes Mellitus
Interventions
Libre 2 rt-CGM, POC BG + Blinded CGM
Device · Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
18 Years to 90 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 3, 2026, 5:27 AM EST
Not yet recruiting Phase 1 Interventional

A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes

NCT07881887
View directory record Official record
Conditions
Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions
LY4167586, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Anaheim, California • Los Alamitos, California • Walnut Creek, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 3, 2026, 5:27 AM EST
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

NCT01064414
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
26
States / cities
Concord, California • Fountain Valley, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Nov 3, 2026, 5:27 AM EST
Recruiting Phase 3 Interventional

Safest Choice of Antihypertensive Regimen for Postpartum Hypertension

NCT05551104
View directory record Official record
Conditions
Postpartum Complication, Maternal Hypertension, High Blood Pressure
Interventions
Oral Nifedipine, Oral Labetalol
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 3, 2026, 5:27 AM EST
Completed Not applicable Interventional

Multidimensional Prehabilitation in Pancreatic Surgery for Pancreatic and Periampullary Neoplasms

NCT05225038
View directory record Official record
Conditions
Pancreatic Neoplasms, Periampullary Carcinoma
Interventions
Exercise, Nutritional, Behavioral Medicine, Smoking Cessation
Other · Dietary Supplement · Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 3, 2026, 5:27 AM EST
Recruiting Phase 1 Interventional

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT05091424
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Interventions
Mosunetuzumab, Tocilizumab, Venetoclax, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
5
States / cities
Rochester, Minnesota • New York, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 3, 2026, 5:27 AM EST
Completed Phase 4 Interventional Results available

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

NCT02957682
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Praluent (Alirocumab), Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
40 Years to 85 Years
Enrollment
2,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
73
States / cities
Auburn, Alabama • Birmingham, Alabama • Mobile, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Nov 3, 2026, 5:27 AM EST
Completed Phase 2 Interventional

A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor

NCT05021991
View directory record Official record
Conditions
Essential Tremor
Interventions
100 mg PRAX-944, 60 mg PRAX-944, Placebo, Flexibly dosed 20 mg to 100 mg PRAX-944
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Nov 3, 2026, 5:27 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females

NCT00924560
View directory record Official record
Conditions
Bone Mineral Density
Interventions
91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
12 Years to 18 Years · Female only
Enrollment
1,361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Nov 3, 2026, 5:27 AM EST
Completed Phase 3 Interventional Results available

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).

NCT00863746
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Fayetteville, Arkansas • Stanford, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Nov 3, 2026, 5:27 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Nov 3, 2026, 5:27 AM EST
Completed Phase 2 Interventional Results available

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

NCT03981822
View directory record Official record
Conditions
Condylomata Acuminata, Papillomavirus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Sexually Transmitted Diseases, Viral, Sexually Transmitted Diseases, Warts
Interventions
VP-102 and applicator, Placebo
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Plainfield, Indiana • Baton Rouge, Louisiana • Clarkston, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Nov 3, 2026, 5:27 AM EST
Completed No phase listed Observational

Valproic Acid-associated Hypoalbuminemia in Medically Fragile Patients

NCT00723762
View directory record Official record
Conditions
Hypoalbuminemia
Interventions
Specimen collection
Procedure
Lead sponsor
Akron Children's Hospital
Other
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Mantua, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Nov 3, 2026, 5:27 AM EST
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis

NCT01848041
View directory record Official record
Conditions
Blepharoptosis
Interventions
RVL-1201, RVL-1201 Vehicle Placebo
Drug
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Morrow, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Nov 3, 2026, 5:27 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Clinical Utility of Resistance Training for Improving Cardiovascular Disease Risk in Post-Menopausal Women

NCT03752060
View directory record Official record
Conditions
Cardiovascular Risk Factor, Menopause Related Conditions, Neuromuscular Function, Aerobic Capacity, Inflammation
Interventions
Resistance Exercise, Aerobic Exercise
Behavioral
Lead sponsor
Oklahoma State University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Nov 3, 2026, 5:27 AM EST
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen A Zilucoplan

NCT04436497
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Zilucoplan, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Nov 3, 2026, 5:27 AM EST
Enrolling by invitation Phase 2 Interventional

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

NCT06275620
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa
Interventions
AGTC-501 (high dose and standard corticosteroid regimen), AGTC-501 (low dose and standard corticosteroid regimen), AGTC-501 (high dose and modified corticosteroid regimen)
Biological
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
12 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
7
States / cities
Jacksonville, Florida • Miami, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Nov 3, 2026, 5:27 AM EST